Summit Therapeutics (SUMM)

 

Latest News

Summit Therapeutics plc : 3rd Quarter Results

Summit Therapeutics plc: 3rd Quarter Results Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 AND OPERATIONAL PROGRESS Oxford, UK, 15 December 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), th...

Summit Therapeutics plc : Notice of Results

Summit Therapeutics plc: Notice of Results Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 ON 15 DECEMBER 2016 Oxford, UK, 13 December 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery a...

Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid

Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid Summit Therapeutics plc ("Summit" or "the Company") SUMMIT ENROLS PATIENTS IN THE UNITED STATES INTO PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Oxford, UK, 16 November 2016 - Summit Therapeu...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 24 October 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announc...

All News

DateHeadlineSource
15-12-16Summit Therapeutics plc : 3rd Quarter ResultsRNS
13-12-16Summit Therapeutics plc : Notice of ResultsRNS
16-11-16Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of EzutromidRNS
24-10-16Summit Therapeutics plc : Exercise of OptionsRNS
19-10-16Summit Therapeutics plc : Holding(s) in CompanyRNS
14-10-16Summit Therapeutics plc : Exercise of OptionsRNS
11-10-16Summit Therapeutics plc : Exercise of OptionsRNS
07-10-16Summit Therapeutics plc : Exercise of OptionsRNS
06-10-16Summit Presents Preclinical DMD Data at 21st Congress of World Muscle SocietyRNS
04-10-16FTSE closes close to its record high StockMarketWire
04-10-16Why Summit Therapeutics just doubledInteractive Investor
04-10-16Summit Files Form 6-K on Licensing and Collaboration Agreement with Sarepta and Updated Cash GuidanceRNS
04-10-16Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with SareptaRNS
04-10-16Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration AgreementRNS
28-09-16Summit Therapeutics plc : Holding(s) in CompanyRNS
27-09-16Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMDRNS
26-09-16Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMDRNS
08-09-16Summit Therapeutics widens H1 lossStockMarketWire
08-09-16Summit Therapeutics plc : Half-yearly reportRNS
07-09-16Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceRNS
05-09-16Summit Therapeutics plc : Notice of ResultsRNS
09-08-16Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate EzutromidRNS
05-08-16Summit Therapeutics to Present at Canaccord Genuity Growth ConferenceRNS
18-07-16Summit Therapeutics plc : Result of AGMRNS
28-06-16Summit Therapeutics plc : Exercise of OptionsRNS
24-06-16Summit Therapeutics plc : Award of OptionsRNS
21-06-16Summit's Ridinilazole Preserves Microbiome During Treatment of C. Difficile InfectionRNS
17-06-16Summit Therapeutics plc : Notice of AGMRNS
17-06-16First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMDRNS
16-06-16Summit Therapeutics to Present at JMP Securities Life Sciences ConferenceRNS
08-06-16Summit Therapeutics to Host Utrophin R&D Day 15 June 2016RNS
02-06-16Summit Therapeutics plc : 1st Quarter ResultsRNS
31-05-16Summit Therapeutics plc : Notice of ResultsRNS
23-05-16Summit to Present Phase 2 CoDIFy Trial Data at ASM Microbe 2016RNS
12-05-16Summit Therapeutics File US Annual Report on Form 20-FRNS
10-05-16Summit's FY net losses widenStockMarketWire
10-05-16Summit Therapeutics Reports Financial Results for Q4 and Fiscal Year Ended 31 January 2016RNS
06-05-16Summit Therapeutics plc : Notice of ResultsRNS
28-04-16Summit granted further US patent for ridinilazoleStockMarketWire
28-04-16Summit Announces Further US Patent Granted for CDI Antibiotic RidinilazoleRNS

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory